guest ::
| Home > Publications database > One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging. > print |
| Home > Publications database > One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging. > print |
| 001 | 298364 | ||
| 005 | 20251202115945.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-025-07073-w |2 doi |
| 024 | 7 | _ | |a pmid:39883139 |2 pmid |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-00262 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Calderón, Eduardo |0 0009-0000-3837-7151 |b 0 |
| 245 | _ | _ | |a One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2025 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1748597464_24473 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Jun;52(7):2463-2476 |
| 520 | _ | _ | |a Somatostatin receptor (SSTR)-PET is crucial for effective treatment stratification of neuroendocrine neoplasms (NENs). In highly proliferating or poorly differentiated NENs, dual-tracer approaches using additional [18F]FDG PET can effectively identify SSTR-negative disease, usually requiring separate imaging sessions. We evaluated the feasibility of a one-day dual-tracer imaging protocol with a low activity [18F]FDG PET followed by an SSTR-PET using the recently introduced [18F]SiFAlin-TATE tracer in a long axial field-of-view (LAFOV) PET/CT scanner and its implications in patient management.Twenty NEN patients were included in this study. Initially, a low activity [18F]FDG PET was performed (0.5 ± 0.01 MBq/kg; PET scan 60 min p.i.). After 4.2 ± 0.09 h after completion of the [18F]FDG PET, a standard activity of [18F]SiFAlin-TATE was administered (3.0 MBq/kg; PET scan 90 min p.i.). To ensure the quantification accuracy of the second scan, we evaluated the potential impact of residual [18F]FDG activity by segmenting organs with minimal physiological SSTR-tracer uptake, such as the brain and myocardium, and assessing the activity concentrations (ACTs) of tumor lesions. Residual tumor lesion ACTs of [18F]FDG were calculated by factoring fluorine-18 decay, identifying a maximum residual ACT of 15% (R15%). To account for increased [18F]FDG trapping over time, higher residual ACTs of 20% (R20%) were considered. These simulated [18F]FDG ACTs were compared with those measured in the second PET scan with [18F]SiFAlin-TATE. The influence of the dual-tracer PET/CT results on therapeutic strategies was evaluated.[18F]FDG cerebral uptake significantly decreased in the subsequent SSTR-PET (mean uptake [18F]FDG: SUVmean 6.0 ± 0.4; mean uptake in [18F]SiFAlin-TATE PET: SUVmean 0.2 ± 0.01; p < 0.0001); with similar results recorded for the myocardium. Simulated residual [18F]FDG ACTs represented only a minimal percentage of ACTs measured in the tumor lesions from the second PET scan (R15%: mean 5.2 ± 0.9% and R20%: mean 6.8 ± 1.2%), indicating only minimal residual activity of [18F]FDG that might interfere with the second PET scan using [18F]SiFAlin-TATE and preserved semi-quantification of the latter. Dual-tracer PET/CT findings directly influenced changes in therapy plans in eleven (55%) of the examined patients.LAFOV PET scanners enable a one-day dual-tracer protocol, providing diagnostic image quality while preserving the semi-quantification of two 18F-labeled radiotracers, potentially simplifying the assessment of tumor biology and improving the clinical patient management while reducing logistical challenges. Additionally, low-activity PET imaging facilitates one-day dual-tracer PET examinations. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Dual-tracer PET |2 Other |
| 650 | _ | 7 | |a LAFOV PET/CT |2 Other |
| 650 | _ | 7 | |a Low activity [18F]FDG PET |2 Other |
| 650 | _ | 7 | |a Neuroendocrine neoplasms |2 Other |
| 700 | 1 | _ | |a Kiefer, Lena S |b 1 |
| 700 | 1 | _ | |a Schmidt, Fabian P |b 2 |
| 700 | 1 | _ | |a Lan, Wenhong |b 3 |
| 700 | 1 | _ | |a Brendlin, Andreas S |b 4 |
| 700 | 1 | _ | |a Reinert, Christian P |b 5 |
| 700 | 1 | _ | |a Singer, Stephan |b 6 |
| 700 | 1 | _ | |a Reischl, Gerald |b 7 |
| 700 | 1 | _ | |a Hinterleitner, Martina |b 8 |
| 700 | 1 | _ | |a Dittmann, Helmut |b 9 |
| 700 | 1 | _ | |a la Fougère, Christian |0 0000-0001-7519-0417 |b 10 |
| 700 | 1 | _ | |a Trautwein, Nils F |0 0000-0003-3397-6299 |b 11 |
| 773 | _ | _ | |a 10.1007/s00259-025-07073-w |0 PERI:(DE-600)2098375-X |n 7 |p 2463-2476 |t European journal of nuclear medicine and molecular imaging |v 52 |y 2025 |x 1619-7070 |
| 856 | 4 | _ | |y OpenAccess |u https://inrepo02.dkfz.de/record/298364/files/s00259-025-07073-w.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://inrepo02.dkfz.de/record/298364/files/s00259-025-07073-w.pdf?subformat=pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:298364 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 0000-0001-7519-0417 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-05 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-05 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-05 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-05 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-05 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-05 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-05 |
| 920 | 1 | _ | |0 I:(DE-He78)TU01-20160331 |k TU01 |l DKTK Koordinierungsstelle Tübingen |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-He78)TU01-20160331 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|